Frederick Jane, Virk Ranya K A, Ye I Chae, Almassalha Luay M, Wodarcyk Greta M, VanDerway David, Gonzalez Paola Carrillo, Nap Rikkert J, Agrawal Vasundhara, Anthony Nicholas M, Carinato John, Li Wing Shun, Dunton Cody L, Medina Karla I, Kakkaramadam Rivaan, Jain Surbhi, Shahabi Shohreh, Ameer Guillermo, Szleifer Igal G, Backman Vadim
Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA.
Center for Physical Genomics and Engineering, Northwestern University, Evanston, IL 60208, USA.
bioRxiv. 2024 Nov 15:2024.11.14.623612. doi: 10.1101/2024.11.14.623612.
Cancer cells exhibit a remarkable resilience to cytotoxic stress, often adapting through transcriptional changes linked to alterations in chromatin structure. In several types of cancer, these adaptations involve epigenetic modifications and restructuring of topologically associating domains (TADs). However, the underlying principles by which chromatin architecture facilitates such adaptability across different cancers remain poorly understood. To investigate the role of chromatin in this process, we developed a physics-based mechanistic model that connects chromatin organization to cell fate decisions, specifically survival following chemotherapy. Our model builds on the observation that chromatin forms packing domains, which influence transcriptional efficiency through macromolecular crowding. The model accurately predicts chemoevasion , suggesting that changes in packing domains affect the likelihood of survival. Consistent results across diverse cancer types indicate that the model captures fundamental principles of chromatin-mediated adaptation, independent of the specific cancer or chemotherapy mechanisms involved. Based on these insights, we hypothesized that compounds capable of modulating packing domains, termed Transcriptional Plasticity Regulators (TPRs), could prevent cellular adaptation to chemotherapy. Using live-cell chromatin imaging, we conducted a compound screen that identified several TPRs which synergistically enhanced chemotherapy-induced cell death. The most effective TPR significantly improved therapeutic outcomes in a patient-derived xenograft (PDX) model of ovarian cancer. These findings underscore the central role of chromatin in cellular adaptation to cytotoxic stress and present a novel framework for enhancing cancer therapies, with broad potential across multiple cancer types.
癌细胞对细胞毒性应激表现出显著的恢复力,通常通过与染色质结构改变相关的转录变化来进行适应。在几种类型的癌症中,这些适应涉及表观遗传修饰和拓扑相关结构域(TADs)的重组。然而,染色质结构促进不同癌症这种适应性的潜在机制仍知之甚少。为了研究染色质在此过程中的作用,我们开发了一种基于物理学的机制模型,该模型将染色质组织与细胞命运决定联系起来,特别是化疗后的存活情况。我们的模型基于这样的观察结果构建:染色质形成包装结构域,其通过大分子拥挤影响转录效率。该模型准确预测了化疗逃避,表明包装结构域的变化会影响存活的可能性。不同癌症类型的一致结果表明,该模型捕捉到了染色质介导的适应的基本原理,与所涉及的特定癌症或化疗机制无关。基于这些见解,我们假设能够调节包装结构域的化合物,称为转录可塑性调节剂(TPRs),可以防止细胞对化疗的适应。通过活细胞染色质成像,我们进行了一项化合物筛选,鉴定出几种TPRs,它们协同增强了化疗诱导的细胞死亡。最有效的TPR在卵巢癌的患者来源异种移植(PDX)模型中显著改善了治疗效果。这些发现强调了染色质在细胞对细胞毒性应激适应中的核心作用,并提出了一个增强癌症治疗的新框架,在多种癌症类型中具有广泛的潜力。